FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年10月3日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 歌禮製藥有限公司 本月底法定/註冊股本總額： USD 700,000 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 7,000,000,000 | USD | | 0.0001 | USD | | 700,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 7,000,000,000 | USD | | 0.0001 | USD | | 700,000 | FF ...

Group 1 - The article reports on share buybacks conducted by various companies on October 2, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1] - Tencent Holdings repurchased 812,000 shares for a total of 550 million, representing 0.725% of its total share capital for the year [2] - Other notable companies involved in the buyback include Hang Seng Bank, which repurchased 200,000 shares for 23.94 million, and Cloud Factory, which repurchased 2 million shares for 9.59 million [2] Group 2 - The total number of shares repurchased by Tencent Holdings year-to-date is 66.625 million [2] - Hang Seng Bank's cumulative repurchase for the year stands at 8.73 million shares [2] - Cloud Factory's cumulative repurchase for the year is 6.109 million shares, indicating a significant buyback activity [2]

智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年10月2日斥资66.61万港元回购6万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年10月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | ...

Group 1 - Pharmaceutical stocks are experiencing a strong rally, with notable increases in share prices for companies such as Clover Biopharmaceuticals (up 20.26%), Genscript Biotech (up 15.05%), and others [1] - On September 26, former President Trump announced a 100% tariff on any brand or patented pharmaceutical products starting October 1, 2025, unless companies establish manufacturing facilities in the U.S. [1] - Southwest Securities predicts uncertainty regarding the implementation of this executive order, suggesting that Chinese innovative drug companies heavily reliant on the U.S. market may face short-term pressure [1] - China’s innovative drug companies that engage in business development (BD) overseas are expected to be less affected, particularly those involved in license-out agreements, which are essentially intellectual property transactions [1] - China Post Securities believes the actual impact of the tariffs will be minimal, viewing the current price drop as a good opportunity to increase holdings in innovative drugs [1] Group 2 - From the perspective of catalysts in the innovative drug sector, October will see significant industry conferences such as ESMO (October 17-21), followed by ASH and the San Antonio Breast Cancer Symposium in December [2] - There has been ongoing progress in outbound licensing transactions this year, with several significant deals already completed, indicating potential opportunities for high-quality domestic innovative drugs to enter international markets [2] - The fourth quarter is expected to bring domestic policy implementations, including adjustments to the medical insurance catalog [2]

Core Viewpoint - The company, Gilead Sciences (1672.HK), announced a share buyback plan, which has led to a nearly 13% increase in its stock price, reaching HKD 11.25. The buyback is intended to enhance shareholder value and reflects the company's confidence in its long-term business prospects [1]. Financial Position - The company stated that its current financial condition is stable, allowing it to allocate up to HKD 300 million for the share buyback [1]. - The buyback authorization permits the company to repurchase up to 96.2846 million shares, which is equivalent to 10% of the total issued shares [1]. Strategic Intent - The board believes that the proposed share buyback will increase the value of the shares and improve returns for shareholders [1]. - The decision to repurchase shares demonstrates the company's confidence in its growth potential and long-term business outlook, which is expected to ultimately benefit the company and its shareholders [1]. - The company will ensure that the buyback does not significantly impact its operating capital [1].

Core Viewpoint - The company, Gilead Sciences (1672.HK), announced a share buyback plan, which has led to a nearly 13% increase in its stock price, reflecting confidence in its long-term business prospects and growth potential [1] Group 1: Share Buyback Announcement - The company plans to utilize up to 300 million HKD from its internal financial resources for the proposed share buyback [1] - The buyback authorization allows the company to repurchase up to 96.2846 million shares, representing 10% of the total issued shares [1] - The board believes that the share buyback will enhance shareholder value and returns [1] Group 2: Financial Health and Confidence - The company stated that its current financial condition is stable [1] - The proposed buyback reflects the company's confidence in its long-term business outlook and growth potential [1] - The company will ensure that the buyback does not significantly adversely affect its operating capital [1]

Core Viewpoint - The company, Gilead Sciences-B (01672), has seen its stock price increase by over 10% following the announcement of a share buyback program, reflecting confidence in its long-term business prospects and growth potential [1] Group 1: Share Buyback Announcement - Gilead Sciences announced its intention to repurchase shares based on the general authorization granted by shareholders at the annual general meeting held on May 22 this year [1] - The company is authorized to buy back up to 96.2846 million shares, which represents 10% of the total issued shares (excluding treasury shares) as of the date of the annual general meeting [1] - The board has decided to exercise the buyback authorization and will repurchase shares in the open market as market conditions permit, using up to HKD 300 million from internal financial resources [1] Group 2: Confidence in Business Prospects - The board believes that the proposed share buyback reflects the company's confidence in its long-term business outlook and growth potential [1] - The buyback is expected to benefit the company and align with the overall best interests of the company and its shareholders [1]

于2025年9月29日，董事会已决定行使购回授权，并根据市况不时于公开市场购回股份，以使用最多3亿 港元的资金(拨付自公司内部财务资源)进行建议股份购回。董事会相信，建议股份购回反映公司对自身 的长远业务前景及公司的增长潜力充满信心，且最终将可惠及公司，并符合公司及公司股东整体的最佳 利益。 消息面上，歌礼制药公布，其拟根据公司股东于今年5月22日举行的公司股东周年大会上授予董事会购 回公司股份的一般授权行使其权力，在合适时间于公开市场上购回股份。根据购回授权，公司获准购回 最多9628.46万股股份，相当于股东周年大会日期已发行股份(不包括库存股份)总数的10%。 智通财经APP获悉，歌礼制药-B(01672)涨超10%，截至发稿，涨10.23%，报10.99港元，成交额4277.41 万港元。 ...